Padmanee Sharma, M.D., Ph.D.

Peer-Reviewed Articles

1. Sharma P, Goswami S, Raychaudhuri D, Siddiqui BA, Singh P, Nagarajan A, Liu J, Subudhi SK, Poon C, Gant KL, Herbrich SM, Anandhan S, Islam S, Amit M, Anandappa G, Allison JP. Immune checkpoint therapy-current perspectives and future directions. Cell 186(8):1652-1669, 2023. PMID: 37059068.
2. Sharma P, Allison JP. Immune checkpoint therapy: Forging ahead. Sci Transl Med 14(670):eadf2947, 2022. e-Pub 2022. PMID: 36350993.
3. Sharma P, Siddiqui BA, Anandhan S, Yadav SS, Subudhi SK, Gao J, Goswami S, Allison JP. The Next Decade of Immune Checkpoint Therapy. Cancer Discov 11(4):838-857, 2021. PMID: 33811120.
4. Sharma P, Pachynski RK, Narayan V, Fléchon A, Gravis G, Galsky MD, Mahammedi H., Patnaik A, Subudhi SK, Ciprotti M, Simsek B, Saci A, Hu Y, Han GC, Fizazi K. Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial. Cancer Cell, 2020. PMID: 32916128.
5. Sharma P, Sohn J, Shin SJ, Oh DY, Keam B, Lee HJ, Gizzi M, Kalinka E, de Vos FYFL, Ruscica D, Ferro S, Xiao F, Baverel P, Chen CC, Asubonteng K, Morsli N, Dirix L. Efficacy and Tolerability of Tremelimumab in Locally Advanced or Metastatic Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based Chemotherapy. Clin Cancer Res 26(1):61-70, 2020. e-Pub 2019. PMID: 31801732.
6. Sharma P, Allison JP. Dissecting the mechanisms of immune checkpoint therapy. Nat Rev Immunol. e-Pub 2020. PMID: 31925406.
7. Sharma P, Siefker-Radtke A, de Braud F, Basso U, Calvo E, Bono P, Morse MA, Ascierto PA, Lopez-Martin J, Brossart P, Rohrberg K, Mellado B, Fischer BS, Meadows-Shropshire S, Abdel Saci , Callahan MK, Rosenberg J. Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results. J Clin Oncol:JCO1900538. e-Pub 2019. PMID: 31100038.
8. Escudier B, Motzer RJ, Sharma P, Wagstaff J, Plimack ER, Hammers HJ, Donskov F, Gurney H, Sosman JA, Zalewski PG, Harmenberg U, McDermott DF, Choueiri TK, Richardet M, Tomita Y, Ravaud A, Doan J, Zhao H, Hardy H, George S. Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025. Eur Urol 72(3):368-376, 2017. e-Pub 2017. PMID: 28410865.
9. Wei SC, Levine JH, Cogdill AP, Zhao Y, Anang NAS, Andrews MC, Sharma P, Wang J, Wargo JA, Pe'er D, Allison JP. Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade. Cell 170(6):1120-1133.e17, 2017. e-Pub 2017. PMID: 28803728.
10. Kamat AM, Bellmunt J, Galsky MD, Konety BR, Lamm DL, Langham D, Lee CT, Milowsky MI, O'Donnell MA, O'Donnell PH, Petrylak DP, Sharma P, Skinner EC, Sonpavde G, Taylor JA, Abraham P, Rosenberg JE. Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma. J Immunother Cancer 5(1):68, 2017. e-Pub 2017. PMID: 28807024.
11. Hammers HJ, Plimack ER, Infante JR, Rini BI, McDermott DF, Lewis LD, Voss MH, Sharma P, Pal SK, Razak ARA, Kollmannsberger C, Heng DYC, Spratlin J, McHenry MB, Amin A. Safety and Efficacy of Nivolumab in Combination with Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study. J Clin Oncol:JCO2016721985. e-Pub 2017. PMID: 28678668.
12. Reuben A, Gittelman RM, Gao J, Zhang J, Yusko E, Wu CJ, Emerson R, Zhang J, Tipton CM, Li J, Quek K, Gopalakrishnan V, Chen R, Vence L, Cascone T, Vignali M, Fujimoto J, Rodriguez-Canales J, Parra ER, Little LD, Gumbs C, Forget MA, Federico L, Haymaker C, Behrens C, Benzeno S, Bernatchez C, Sepesi B, Gibbons DL, Wargo JA, William WN, Swisher SG, Heymach J, Robins H, Lee JJ, Sharma P, Allison JP, Futreal PA, Wistuba II, Zhang J. TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: an Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence. Cancer Discov. e-Pub 2017. PMID: 28733428.
13. Gao J, Ward JF, Pettaway CA, Shi LZ, Subudhi SK, Vence LM, Zhao H, Chen J, Chen H, Efstathiou E, Troncoso P, Allison JP, Logothetis CJ, Wistuba II, Sepulveda MA, Sun J, Wargo J, Blando J, Sharma P. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nat Med 23(5):551-555, 2017. e-Pub 2017. PMID: 28346412.
14. Morris VK, Salem ME, Nimeiri H, Iqbal S, Singh P, Ciombor K, Polite B, Deming D, Chan E, Wade JL, Xiao L, Bekaii-Saab T, Vence L, Blando J, Mahvash A, Foo WC, Ohaji C, Pasia M, Bland G, Ohinata A, Rogers J, Mehdizadeh A, Banks K, Lanman R, Wolff RA, Streicher H, Allison J, Sharma P, Eng C. Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. Lancet Oncol 18(4):446-453, 2017. e-Pub 2017. PMID: 28223062.
15. Escudier B, Sharma P, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Gurney H, Donskov F, Peltola K, Wagstaff J, Gauler TC, Ueda T, Zhao H, Waxman IM, Motzer RJ, CheckMate 025 investigators. CheckMate 025 randomized Phase 3 Study: Outcomes by key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma. Eur Urol. e-Pub 2017. PMID: 28262413.
16. Tang C, Welsh JW, de Groot P, Massarelli E, Chang JY, Hess KR, Basu S, Curran MA, Cabanillas ME, Subbiah V, Fu S, Tsimberidou AM, Karp D, Gomez DR, Diab A, Komaki R, Heymach JV, Sharma P, Naing A, Hong DS. Ipilimumab with stereotactic ablative radiation therapy: Phase I results and immunologic correlates from peripheral T-cells. Clin Cancer Res 23(6):1388-1396, 2017. e-Pub 2016. PMID: 27649551.
17. Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J, Plimack ER, Vaena D, Grimm MO, Bracarda S, Arranz JÁ, Pal S, Ohyama C, Saci A, Qu X, Lambert A, Krishnan S, Azrilevich A, Galsky MD. Nivolumab in metastatic urothelial carcinoma after platinum therapy (Checkmate 275) : a multicentre, single-arm, phase 2 trial. Lancet Oncol 18(3):312-322, 2017. e-Pub 2017. PMID: 28131785.
18. Roh W, Chen PL, Reuben A, Spencer CN, Prieto PA, Miller JP, Gopalakrishnan V, Wang F, Cooper ZA, Reddy SM, Gumbs C, Little L, Chang Q, Chen WS, Wani K, De Macedo MP, Chen E, Austin-Breneman JL, Jiang H, Roszik J, Tetzlaff MT, Davies MA, Gershenwald JE, Tawbi H, Lazar AJ, Hwu P, Hwu WJ, Diab A, Glitza IC, Patel SP, Woodman SE, Amaria RN, Prieto VG, Hu J, Sharma P, Allison JP, Chin L, Zhang J, Wargo JA, Futreal PA. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Transl Med 9(379), 2017. PMID: 28251903.
19. Lu X, Horner JW, Paul E, Shang X, Troncoso P, Deng P, Jiang S, Chang Q, Spring DJ, Sharma P, Zebala JA, Maeda DY, Wang YA, DePinho RA. Effective combinatorial immunotherapy for castration-resistant prostate cancer. Nature 543(7647):728-732, 2017. e-Pub 2017. PMID: 28321130.
20. Wang X, Schoenhals JE, Li A, Valdecanas DR, Ye H, Zang F, Tang C, Tang M, Liu CG, Liu X, Krishnan S, Allison JP, Sharma P, Hwu P, Komaki R, Overwijk WW, Gomez DR, Chang JY, Hahn SM, Cortez MA, Welsh JW. Suppression of type I IFN signaling in tumors mediates resistance to anti-PD-1 treatment that can be overcome by radiotherapy. Cancer Res 77(4):839-850, 2017. e-Pub 2016. PMID: 27821490.
21. Haymaker CL, Kim D, Uemura M, Vence LM, Phillip A, McQuail N, Brown PD, Fernandez I, Hudgens CW, Creasy C, Hwu WJ, Sharma P, Tetzlaff MT, Allison JP, Hwu P, Bernatchez C, Diab A. Metastatic melanoma patient had complete response with clonal expansion after whole brain radiation and PD-1 blockade. Cancer Immunol Res 5(2):100-105, 2017. e-Pub 2017. PMID: 28062513.
22. Zamarin D, Holmgaard RB, Ricca J, Plitt T, Palese P, Sharma P, Merghoub T, Wolchok JD, Allison JP. Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity. Nat Commun 8:14340, 2017. e-Pub 2017. PMID: 28194010.
23. Reilley MJ, Bailey A, Subbiah V, Janku F, Naing A, Falchook G, Karp D, Piha-Paul S, Tsimberidou A, Fu S, Lim J, Bean S, Bass A, Montez S, Vence L, Sharma P, Allison J, Meric-Bernstam F, Hong DS. Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies. J Immunother Cancer 5:35, 2017. e-Pub 2017. PMID: 28428884.
24. Reuben A, Spencer CN, Prieto PA, Gopalakrishnan V, Reddy SM, Miller JP, Mao X, De Macedo MP, Chen J, Song X, Jiang H, Chen PL, Beird HC, Garber HR, Roh W, Wani K, Chen E, Haymaker C, Forget MA, Little LD, Gumbs C, Thornton RL, Hudgens CW, Chen WS, Austin-Breneman J, Sloane RS, Nezi L, Cogdill AP, Bernatchez C, Roszik J, Hwu P, Woodman SE, Chin L, Tawbi H, Davies MA, Gershenwald JE, Amaria RN, Glitza IC, Diab A, Patel SP, Hu J, Lee JE, Grimm EA, Tetzlaff MT, Lazar AJ, Wistuba II, Clise-Dwyer K, Carter BW, Zhang J, Futreal PA, Sharma P, Allison JP, Cooper ZA, Wargo JA. Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. NPJ Genom Med 2, 2017. e-Pub 2017. PMID: 28819565.
25. McArthur HL, Diab A, Page DB, Yuan J, Solomon SB, Sacchini V, Comstock C, Durack JC, Maybody M, Sung J, Ginsberg A, Wong P, Barlas A, Dong Z, Zhao C, Blum B, Patil S, Neville D, Comen EA, Morris EA, Kotin A, Brogi E, Wen YH, Morrow M, Lacouture ME, Sharma P, Allison JP, Hudis CA, Wolchok JD, Norton L. A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling. Clin Cancer Res 22(23):5729-5737, 2016. e-Pub 2016. PMID: 27566765.
26. Sharma P, Callahan MK, Bono P, Kim J, Spiliopoulou P, Calvo E, Pillai RN, Ott PA, de Braud F, Morse M, Le DT, Jaeger D, Chan E, Harbison C, Lin CS, Tschaika M, Azrilevich A, Rosenberg JE. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. Lancet Oncol 17(11):1590-1598, 2016. e-Pub 2016. PMID: 27733243.
27. Gao J, Shi LZ, Zhao H, Chen J, Xiong L, He Q, Chen T, Roszik J, Bernatchez C, Woodman SE, Chen PL, Hwu P, Allison JP, Futreal A, Wargo JA, Sharma P. Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy. Cell 167(2):397-404.e9, 2016. e-Pub 2016. PMID: 27667683.
28. Subudhi SK, Aparicio A, Gao J, Zurita AJ, Araujo JC, Logothetis CJ, Tahir SA, Korivi BR, Slack RS, Vence L, Emerson RO, Yusko E, Vignali M, Robins HS, Sun J, Allison JP, Sharma P. Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities. Proc Natl Acad Sci U S A 113(42):11919-11924, 2016. e-Pub 2016. PMID: 27698113.
29. Uemura M, Trinh VA, Haymaker C, Jackson N, Kim DW, Allison JP, Sharma P, Vence L, Bernatchez C, Hwu P, Diab A. Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn's disease: a case report. J Hematol Oncol 9(1):81, 2016. e-Pub 2016. PMID: 27595932.
30. Chen PL, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, Miller JP, Bassett RL, Gopalakrishnan V, Wani K, De Macedo MP, Austin-Breneman JL, Jiang H, Chang Q, Reddy SM, Chen WS, Tetzlaff MT, Broaddus RJ, Davies MA, Gershenwald JE, Haydu L, Lazar AJ, Patel SP, Hwu P, Hwu WJ, Diab A, Glitza IC, Woodman SE, Vence LM, Wistuba II, Amaria RN, Kwong LN, Prieto V, Davis RE, Ma W, Overwijk WW, Sharpe AH, Hu J, Futreal PA, Blando J, Sharma P, Allison JP, Chin L, Wargo JA. Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discov 6(8):827-37, 2016. e-Pub 2016. PMID: 27301722.
31. Shi LZ, Fu T, Guan B, Chen J, Blando JM, Allison JP, Xiong L, Subudhi SK, Gao J, Sharma P. Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy. Nat Commun 7:12335, 2016. e-Pub 2016. PMID: 27498556.
32. Metzger TC, Long H, Potluri S, Pertel T, Bailey-Bucktrout SL, Lin JC, Fu T, Sharma P, Allison JP, Feldman RM. ICOS Promotes the Function of CD4+ Effector T Cells during Anti-OX40-Mediated Tumor Rejection. Cancer Res 76(13):3684-9, 2016. e-Pub 2016. PMID: 27197182.
33. Antonia SJ, López-Martin JA, Bendell J, Ott PA, Taylor M, Eder JP, Jäger D, Pietanza MC, Le DT, de Braud F, Morse MA, Ascierto PA, Horn L, Amin A, Pillai RN, Evans J, Chau I, Bono P, Atmaca A, Sharma P, Harbison CT, Lin CS, Christensen O, Calvo E. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol 17(7):883-95, 2016. e-Pub 2016. PMID: 27269741.
34. Cooper ZA, Reuben A, Spencer CN, Prieto PA, Austin-Breneman JL, Jiang H, Haymaker C, Gopalakrishnan V, Tetzlaff MT, Frederick DT, Sullivan RJ, Amaria RN, Patel SP, Hwu P, Woodman SE, Glitza IC, Diab A, Vence LM, Rodriguez-Canales J, Parra ER, Wistuba II, Coussens LM, Sharpe AH, Flaherty KT, Gershenwald JE, Chin L, Davies MA, Clise-Dwyer K, Allison JP, Sharma P, Wargo JA. Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. Oncoimmunology 5(3):e1136044, 2016. e-Pub 2016. PMID: 27141370.
35. Bilen MA, Subudhi SK, Gao J, Tannir NM, Tu SM, Sharma P. Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody. J Immunother Cancer 4:36, 2016. e-Pub 2016. PMID: 27330809.
36. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Choueiri TK, Gurney H, Donskov F, Bono P, Wagstaff J, Gauler TC, Ueda T, Tomita Y, Schutz FA, Kollmannsberger C, Larkin J, Ravaud A, Simon JS, Xu LA, Waxman IM, Sharma P, CheckMate 025 Investigators. Nivolumab versus Everolimus in Advanced Renal Cell Carcinoma. N Engl J Med 373(19):1803-13, 2015. e-Pub 2015. PMID: 26406148.
37. Gao J, He Q, Subudhi S, Aparicio A, Zurita-Saavedra A, Lee DH, Jimenez C, Suarez-Almazor M, Sharma P. Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience. Oncogene 34(43):5411-7, 2015. e-Pub 2015. PMID: 25659583.
38. Liu XD, Hoang A, Zhou L, Kalra S, Yetil A, Sun M, Ding Z, Zhang X, Bai S, German P, Tamboli P, Rao P, Karam JA, Wood C, Matin S, Zurita A, Bex A, Griffioen AW, Gao J, Sharma P, Tannir N, Sircar K, Jonasch E. Resistance to anti-angiogenic therapy is associated with an immunosuppressive tumor microenvironment in metastatic renal cell carcinoma. Cancer Immunol Res 3(9):1017-29, 2015. e-Pub 2015. PMID: 26014097.
39. Skoulidis F, Byers LA, Diao L, Papadimitrakopoulou VA, Tong P, Izzo J, Behrens C, Kadara H, Parra ER, Canales JR, Zhang J, Giri U, Gudikote J, Cortez MA, Yang C, Fan Y, Peyton M, Girard L, Coombes KR, Toniatti C, Heffernan TP, Choi M, Frampton GM, Miller V, Weinstein JN, Herbst RS, Wong KK, Zhang J, Sharma P, Mills GB, Hong WK, Minna JD, Allison JP, Futreal A, Wang J, Wistuba II, Heymach JV. Co-occurring genomic alterations define major subsets of KRAS - mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Cancer Discov 5(8):860-77, 2015. e-Pub 2015. PMID: 26069186.
40. Seyedin SN, Schoenhals JE, Lee DA, Cortez MA, Wang X, Niknam S, Tang C, Hong DS, Naing A, Sharma P, Allison JP, Chang JY, Gomez DR, Heymach JV, Komaki RU, Cooper LJ, Welsh JW. Strategies for combining immunotherapy with radiation for anticancer therapy. Immunotherapy 7(9):967-80, 2015. e-Pub 2015. PMID: 26310908.
41. Özdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X, Wu CC, Simpson TR, Laklai H, Sugimoto H, Kahlert C, Novitskiy SV, De Jesus-Acosta A, Sharma P, Heidari P, Mahmood U, Chin L, Moses HL, Weaver VM, Maitra A, Allison JP, LeBleu VS, Kalluri R. Depletion of carcinoma-associated fibroblasts and fibrosis stimulates immunosuppression and accelerates pancreatic cancer with diminished survival. Cancer Cell 25(6):719-34, 2014. e-Pub 2014. PMID: 24856586.
42. Fan X, Quezada SA, Sepulveda MA, Sharma P, Allison JP. Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy. J Exp Med 211(4):715-25, 2014. e-Pub 2014. PMID: 24687957.
43. Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, Su X, Wang Y, Gonzalez-Angulo AM, Akcakanat A, Chawla A, Curran M, Hwu P, Sharma P, Litton JK, Molldrem JJ, Alatrash G. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res 2(4):361-70, 2014. e-Pub 2014. PMID: 24764583.
44. Chen H, Fu T, Suh WK, Tsavachidou D, Wen S, Gao J, Ng Tang D, He Q, Sun J, Sharma P. CD4 T cells require ICOS-mediated PI3K signaling to increase T-Bet expression in the setting of anti-CTLA-4 therapy. Cancer Immunol Res 2(2):167-76, 2014. e-Pub 2013. PMID: 24778280.
45. Plimack ER, Desai JR, Issa JP, Jelinek J, Sharma P Vence LM, Bassett RL, Ilagan JL, Papadopoulos NE, Hwu WJ. A phase I study of decitabine with pegylated interferon α-2b in advanced melanoma: impact on DNA methylation and lymphocyte populations. Invest New Drugs. e-Pub 2014.
46. Ng Tang D, Shen Y, Sun J, Wen S, Wolchok JD, Yuan J, Allison JP, Sharma P. Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy. Cancer Immunol Res 1:229-234, 2013.
47. Richey SL, Tamboli P, NG CS, Lim ZD, Araujo JC, Jonasch E, Sharma P, Pagliaro LC, Tannir NM. Phase II trial of Pemetrexed plus Gemcitabine in patients with locally advanced and metastatic non-clear cell renal cell carcinoma. Am J Clin Oncol, 2012. PMID: 22706175.
48. Sun J, Tang DN, Fu T, Sharma P. Identification of human regulatory T cells in the setting of T cell activation and anti-CTLA-4 immunotherapy based on expression of latency associated peptide (LAP). Cancer Discov 2(2):122-30, 2012. e-Pub 2011. PMID: 22585857.
49. Fu T, He Q, Sharma P. The ICOS/ICOSL pathway is required for optimal anti-tumor responses mediated by anti-CTLA-4 therapy. Cancer Res 71(16):5445-54, 2011. e-Pub 2011. PMID: 21708958.
50. Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA, Atkins MB, Bartunkova J, Bergmann L, Berinstein N, Bonorino CC, Borden E, Bramson JL, Britten CM, Cao X, Carson WE, Chang AE, Characiejus D, Choudhury AR, Coukos G, de Gruijl T, Dillman RO, Dolstra H, Dranoff G, Durrant LG, Finke JH, Galon J, Gollob JA, Gouttefangeas C, Grizzi F, Guida M, Håkansson L, Hege K, Herberman RB, Hodi FS, Hoos A, Huber C, Hwu P, Imai K, Jaffee EM, Janetzki S, June CH, Kalinski P, Kaufman HL, Kawakami K, Kawakami Y, Keilholtz U, Khleif SN, Kiessling R, Kotlan B, Kroemer G, Lapointe R, Levitsky HI, Lotze MT, Maccalli C, Maio M, Marschner JP, Mastrangelo MJ, Masucci G, Melero I, Melief C, Murphy WJ, Nelson B, Nicolini A, Nishimura MI, Odunsi K, Ohashi PS, O'Donnell-Tormey J, Old LJ, Ottensmeier C, Papamichail M, Parmiani G, Pawelec G, Proietti E, Qin S, Rees R, Ribas A, Ridolfi R, Ritter G, Rivoltini L, Romero PJ, Salem ML, Scheper RJ, Seliger B, Sharma P, Shiku H, Singh-Jasuja H, Song W, Straten PT, Tahara H, Tian Z, van Der Burg SH, von Hoegen P, Wang E, Welters MJ, Winter H, Withington T, Wolchok JD, Xiao W, Zitvogel L, Zwierzina H, Marincola FM, Gajewski TF, Wigginton JM, Disis ML. Defining the critical hurdles in cancer immunotherapy. J Transl Med 9(1):214, 2011. e-Pub 2011. PMID: 22168571.
51. Carthon BC, Wolchok JD, Yuan J, Kamat A, Ng Tang DS, Sun J, Ku G, Troncoso P, Logothetis CJ, Allison JP, Sharma P. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res 16(10):2861-71, 2010. PMID: 20460488.
52. Matin SF, Sharma P, Gill IS, Tannenbaum C, Hobart MG, Novick AC, Finke JH. Immunologic response to renal cryoablation in an in vivo orthotopic renal cell carcinoma murine model. J Urol 183(1):333-8, 2010. PMID: 19914660.
53. Gnjatic S, Altorki NK, Tang DN, Tu SM, Kundra V, Ritter G, Old LJ, Logothetis CJ, Sharma P. NY-ESO-1 DNA vaccine induces T cell responses that are suppressed by regulatory T cells. Clin Cancer Res 15(6):2130-9, 2009. e-Pub 2009. PMID: 19276258.
54. Chen H, Liakou CI, Kamat A, Pettaway C, Ward JF, Tang DN, Sun J, Jungbluth AA, Troncoso P, Logothetis C, Sharma P. Anti-CTLA-4 therapy results in higher CD4⁺ICOS^hi T cell frequency and IFN-{gamma} levels in both nonmalignant and malignant prostate tissues. Proc Natl Acad Sci U S A 106(8):2729-34, 2009. PMID: 19202079.
55. Sharma P, Bajorin DF, Jungbluth AA, Herr H, Old LJ, Gnjatic S. Immune responses detected in urothelial carcinoma patients after vaccination with NY-ESO-1 protein plus BCG and GM-CSF. J Immunother 31(9):849-57, 2008. PMID: 18833002.
56. Liakou CI, Kamat A, Tang DN, Chen H, Sun J, Troncoso P, Logothetis C, Sharma P. CTLA-4 blockade increases IFNgamma-producing CD4⁺ICOS^hi T cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci U S A 105(39):14987-92, 2008. e-Pub 2008. PMID: 18818309.
57. Sun J, Schiffman J, Raghunath A, Ng Tang D, Chen H, Sharma P. Concurrent decrease in IL-10 with development of immune-related adverse events in a patient treated with anti-CTLA-4 therapy. Cancer Immun 8:9, 2008. PMID: 18503261.
58. Zang X, Thompson RH, Al-Ahmadie HA, Serio AM, Reuter VE, Eastham JA, Scardino PT, Sharma P, Allison JP. B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci U S A 104(49):19458-63, 2007. e-Pub 2007. PMID: 18042703.
59. Kopetz S, Jimenez CA, Tu SM, Sharma P. Pulmonary arteriovenous fistula in a patient with renal cell carcinoma. Eur Resp J 29(4):813-5, 2007. PMID: 17400880.
60. Sharma P, Shen Y, Wen S, Yamada S, Jungbluth AA, Gnjatic S, Bajorin DF, Reuter VE, Herr H, Old LJ, Sato E. CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci U S A 104(10):3967-72, 2007. PMID: 17360461.
61. Sharma P, Shen Y, Wen S, Bajorin DF, Reuter VE, Old LJ, Jungbluth AA. Cancer-testis antigens: expression and correlation with survival in human urothelial carcinoma. Clin Cancer Res 12(18):5442-7, 2006. PMID: 17000678.
62. Sharma P, Gnjatic S, Jungbluth AA, Williamson B, Herr H, Stockert E, Dalbagni G, Donat SM, Reuter VE, Santiago D, Chen YT, Bajorin DF, Old LJ. Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T cell epitope in a patient with bladder cancer. Cancer Immun 3:19, 2003. PMID: 14680360.
63. Sharma P, Page MJ, Poritz LS, Koltun WA, Chorney MJ. An increased gamma delta T cell population in the intestine of thymus-leukemia antigen transgenic mice. Cell Immunol 176(2):153-7, 1997. PMID: 9073388.
64. Sharma P, Johnson CA, Bonneau RH, Lang CM, Chorney MJ. Transgenic mice expressing the thymus leukemia antigen fail to control cutaneous herpes simplex virus infection. Cell Immunol 174(1):84-9, 1996. PMID: 8929457.
65. Joyce S, Negishi I, Boestanu A, DeSilva DA, Sharma P , Chorney MJ, Loh DY, Van Kaer L. Expansion of natural (NK1+) T cells that express alpha/beta T-cell receptors in transporters associated with antigen presentation-1 null and thymus-leukemia antigen positive mice. J Exp Med 184(4):1579-84, 1996. PMID: 8879233.
66. Venditti CP, Lawlor DA, Sharma P, Chorney MJ. Structure and content of the major histocompatibility complex (MHC) class I regions of the great anthropoid apes. H Immunol 49(2):71-84, 1996. PMID: 8872161.
67. Sharma P, Joyce S, Chorney K, Griffith J, Bonneau RH, Wilson F, Flavell R, Chorney MJ.. Thymus-leukemia antigen, T18d, interacts with T cells and self peptides. J Immunol 156(3):987-96, 1996. PMID: 8558026.

Invited Articles

1. Boddu P, Kantarjian H, Garcia-Manero G, Allison J, Sharma P, Daver N. The emerging role of immune checkpoint based approaches in AML and MDS. Leuk Lymphoma:1-13. e-Pub 2017. PMID: 28679300.
2. Goswami S, Sharma P. Genetic biomarker for cancer immunotherapy. Science 357(6349):358, 2017. PMID: 28751597.
3. Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell 168(4):707-723, 2017. PMID: 28187290.
4. Masarova L, Kantarjian H, Garcia-Mannero G, Ravandi F, Sharma P, Daver N. Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML. Adv Exp Med Biol 995:73-95, 2017. PMID: 28321813.
5. Wargo JA, Reddy SM, Reuben A, Sharma P. Monitoring immune responses in the tumor microenvironment. Curr Opin Immunol 41:23-31, 2016. e-Pub 2016. PMID: 27240055.
6. Sharma P. Immune Checkpoint Therapy and the Search for Predictive Biomarkers. The Cancer Journal 22(2):68-72, 2016.
7. Neelapu SS, Sharma P. Targeting the tumor niche to treat cancer. Proc Natl Acad Sci U S A 112(42):12907-8, 2015. e-Pub 2015. PMID: 26450879.
8. Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 161(2):205-14, 2015. PMID: 25860605.
9. Sharma P, Allison JP. The future of immune checkpoint therapy. Science 348(6230):56-61, 2015. PMID: 25838373.
10. Tang C, Wang X, Soh H, Seyedin S, Cortez MA, Krishnan S, Massarelli E, Hong D, Naing A, Diab A, Gomez D, Ye H, Heymach J, Komaki R, Allison JP, Sharma P, Welsh JW. Combining radiation and immunotherapy: a new systemic therapy for solid tumors?. Cancer Immunol Res 2(9):831-8, 2014. PMID: 25187273.
11. Harshman LC, Drake CG, Wargo JA, Sharma P, Bhardwaj N. Cancer Immunotherapy Highlights from the 2014 ASCO Meeting. Cancer Immunol Res 2(8):714-9, 2014. PMID: 25092813.
12. Raval RR, Sharabi AB, Walker AJ, Drake CG, Sharma P|. Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer. J Immunother Cancer 2:14, 2014. PMID: 24883190.
13. Drake CG, Sharma P, Gerritsen W. Metastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapy. Oncogene. e-Pub 2013. PMID: 24276248.
14. Gao JJ, Bernatchez C, Sharma P, Radvanyi LG, Hwu P. Advances in the development of cancer immunotherapies. Trends Immunol 34(2):90-8, 2013. PMID: 23031830.
15. Sharma P, Logothetis C. Prostate cancer: Combination of vaccine plus ipilimumab-safety and toxicity. Nat Rev Urol 9(6):302-3, 2012. e-Pub 2012. PMID: 22565371.
16. Gerritsen WR, Sharma P. Current and emerging treatment options for castration-resistant prostate cancer: A focus on immunotherapy. J Clin Immunol 32(1):25-35, 2012. e-Pub 2011. PMID: 22048979.
17. Sharma P, Allison JP. Retrospective. Lloyd J. Old (1933-2011). Science 335(6064):49, 2012. PMID: 22223799.
18. Sharma P, Wagner K, Wolchok JD, Allison JP. Novel cancer immunotherapy agents with survival benefit: Recent successes and next steps. Nat Rev Cancer 11(11):805-12, 2011. e-Pub 2011. PMID: 22020206.
19. Hammerstrom AE, Cauley DH, Atkinson BJ, Sharma P. Cancer immunotherapy: Sipuleucel-T and beyond. Pharmacotherapy 31(8):813-28, 2011. PMID: 21923608.
20. Sharma P. Cancer immunotherapy: In vivo imaging of adoptively transferred T cells in an immunocompetent host. Proc Natl Acad Sci U S A 107(32):13977-8, 2010. PMID: 20671198.
21. Mittendorf EA, Sharma P. Mechanisms of T cell inhibition: Implications for cancer immunotherapy. Expert Rev Vaccines 9(1):89-105, 2010. PMID: 20021308.
22. Aparicio A, Sharma P, Millikan RE. Experimental systemic therapy of metastatic urothelial cancer. In: UpToDate, Basow, DS (Ed), UpToDate, Waltham, MA, 2009.
23. Carthon B, Sharma P. Advanced urothelial carcinoma: Current treatment strategies and novel agents in clinical trials. CML Urology 14:57-68, 2009. PMID: 20460488.
24. Liakou CI, Narayanan S, Ng Tang D, Logothetis CJ, Sharma P. Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in bladder cancer. Cancer Immun 7:10, 2007. PMID: 17591743.
25. Sharma P, Old LJ, Allison JP. Immunotherapeutic strategies for high risk bladder cancer. Semin Oncol 34(2):165-72, 2007. PMID: 17382800.
26. Pagliaro LC, Sharma P. Review of treatment strategies for metastatic bladder cancer. Minerva Urol Nefrol 58:53-71, 2006. PMID: 16760884.
27. Sharma P, Donat MS, Herr H, Bajorin D. Treatment of locally advanced bladder cancer. Princ Prac Oncol Updates 16:8, 2001.

Editorials

1. Sharma P. From the Guest Editor: Immune Checkpoint Therapy as a Weapon Against Cancer. Cancer J 22(2):67, Mar-Apr, 2016. PMID: 27111899.

Abstracts

1. Daver NG, Basu S, Garcia-Manero G, Cortes JE, Ravandi F, Jabbour E, Hendrickson S, Brandt M, Peirce S, Gordon T, Pemmaraju N, Andreeff M, Ning J, Kornblau S, Kadia TM, Dinardo CD, Konopleva M, Allison JP, Kantarjian HM,Sharma P. Phase IB/II Study of Nivolumab with Azacytidine (AZA) in Patients (pts) with Relapsed AML. American Society for Clinical Oncology, 2017.
2. Reiller M, Basu S, Katkhuda R, Patterson N, Blanco JM, Menter D, Allison JA, Kopetz S,Sharma P, Overman MJ. Prognostic implications of TAMs in colorectal cancer hepatic metastases. American Society for Clinical Oncology, 2017.
3. Janjigian YY, Ott PA, Calvo E, Kim JW, Ascierto PA, Sharma P, Peltola KJ, Jaeger D, Evans J, De Braud FG, Chau I, Tschaika M, Harbison CT, Cai W, Bendell JC, Le DT. Nivolumab+Ipilimumab in pts with advanced (adv)/metastatic chemotherapy-refractory(CTx-R) gastric (G), esophagel (E), or gastroesophageal junction (GEJ) cancer: CheckMate 032 study. American Society for Clinical Oncology, 2017.
4. Necchi A, Grimm MO, Retz M, Arija JAA, Bracarda S, Bedke J, Baron AD, Sharma P, Galsky MD, Vaena DA, Kalinka-Warzocha E, Cwikiel M, Pal SK, Morales R, Taylor F, Gooden KM, Plimack ER. Health-related quality of life as a marker of treatment benefit with nivolumab in platinum-refractory patients with metastatic or unresectable urothelial carcinoma from CheckMate 275. American Society for Clinical Oncology, 2017.
5. Subudhi SK, Aparici A, Troncoso P, Zhang J, Gumbs C, WU CJ, Gao JJ, Vence LM, Blando JM, Corn PG, Araugo JC, Zurita AJ, Prokhorova IN, Van Alstine M, Logothetis C, Futreal A, Allison JP, Sharma P. Linking Tumor Mutational Load to Clinical Responses to Ipilimumab (IPI) in Men with Advanced Prostate Cancer (PCa). American Society for Clinical Oncology, 2017.
6. Gao JJ, Ward JF, Pettaway CA, Shi LZ, Subudhi SK, Vence LM, Zhao H, Chen J, Chen H, Efstathiou E, Troncosco P, Allison JP, Logothetis C, Wistuba II, Wargo JA Blando JM, Sepulveda MA< Sun JJ, Sharma P. Investigation of Mechanisms of Resistance to Ipilimumab Thearapy with a Pre-surgical Trial in Patients with High-Risk, Localized Prostate Cancer. American Society for Clinical Oncology, 2017.
7. Shah AY, Gao JJ, Lemke E, Campbell MT, Qurita AJ, Wang J, Corn PG, Jonasch E, Sharma P, Tannir NM. Responses to second-line tyrosine kinase inhibitors after first-line immune checkpoint inhibitors in advanced renal cell carcinoma. American Society for Clinical Oncology, 2017.
8. Wargo JA, Gopalakrishnan V, Spencer C, Karpinets T, Reuben A, Andrews MC, Tetzlaff MT, Lazar A, Hwu P, Hwu WJ, Glitza IC, Tawbi HAH, Patel SP, Lee JE, Davies MA, Gershenwald JE, Furtreal A, Sharma P, Allison JP, Jenq RR. Diversity and composition of the gut microbiome are associated with enhanced responses and improved progression=free survivak (PFS) in metastatic melanoma (MM) patients (pts) on anti-PD-1 therapy. American Society for Clinical Oncology, 2017.
9. Chen WS, Andrew MC, Spencer C, Tawbi HAH, Lazar A, Tetzlaff MT, Patel SP, Hwu P, Hwu WJ, Diab A, Glitza IC, Amaria RN, Burton EM, Woodman SE, Davies JE,Sharma P, Allison JP, Futreal A, Wargo JA. Molecular and immune predictors of response and toxicity to combined CTLA-4 and PD-1 blockade in metastatic melonoma (MM) patients(pts). American Society for Clinical Oncology, 2017.
10. Davar NG, Garcia-Manero G, Cortes JE, Basu S, Ravandi F, Kadia TM, Borthakyr G, Jabbour E, Dinardo CD, Pemmaraju N, Brandt M, Pierce S, Hussin N, Kornblau SM, Andreef M, Konopleva M, Ning J, Allison JP,Sharma P,Kantarjian HM. Phase IB/II Study of Lirilumab with Azacytidine (AZA) in Relapsed AML. American Society for Clinical Oncology, 2017.
11. Gao JJ, Karam JA, Wood CG, Matin S, Ahrar K, Jonasch E, Tannir N, Campbell M, Ng C, Slack R, Rao P, Allison JP, Blando JM, Vence LM, Basu S, Zhao H, Chen T, Chen H, Sharma P. Clinical activity, immune and molecular correlates of nivolumab vs. nivolumab plus bevacizumab vs nivolumab plus ipilumumab in metastatic renal cell carcinoma. American Association for Cancer Research, 2017.
12. Sharma P, Sohn JH, Shin SJ, Oh D, Keam B, Lee HJ, Canon JL, Kalinka-Warzocha E, Langenberg M, Allison J, Ben Y, Kataria R, Ferro S, Asubonteng K, Dirix L. Efficacy and tolerability of tremelimumab in locally advanced or metastatic urothelial carcinoma. SITC 2017 Annual Meeting Abstracts Book:301-302, 2017.
13. Khouri IF, Curbelo IF, Turturro F, milton DR, Kim RA, Jabbour EJ, Bassett RL, Vence LM, Sharma P , Gulbis AM. Lenalidomide alternating with ipilimumab for lymphoma and chronic lymphocytic leukemia after allogeneic or autologous stem cell transplantation. ASH 2016 Annual Meeting, 2016.
14. Bilen MA, Hess K, Aparicio A, Kim J, Zurita A, Pagliaro LC, Araujo J, Corn P, Atkinson B, Tannir N, Sharma P, Lin SH, Logothetis CJ, Tu SM.. Sipuleucel-T cellular immunotherapy: clinical predictors of cancer-specific death in patients with castration-resistant prostate cancer (CRPCa). American Society for Clinical Oncology, 2016.
15. Morris V, Mahvash A, Vence L,Blando J, Wolff R, Ohinata A, Ohaji C, Allison J, Sharma P, Eng C. A Phase II Study of Nivolumab in refactory Metastatic Squamous Cell Carcinoma of the Anal Canal: Immunologic correlates of response. American Association for Cancer Research, 2016.
16. Subudhi S, Aparicio A, Gao JJ, Zurita-Saavedral A, Araujo J, Logothetis CJ, Brindal K, Allison JA, Vence S, Sharma P. Exploratory biomarkers that predict for clinical outcomes in a Phase II trial with ipilimumab plus finite androgen deprivation therapy for metastatic non-castrate prostate cancer. American Association for Cancer Research, 2016.
17. Subudhi S, Aparicio A, Troncosco P, Zhang J, Gumbs C, Wu CJ, Logothetis CJ, Futreal A, Allison J, Sharma P. A Feasibility study to Determine T Cell Responses to Neoantigens Following Treatment with Ipilimumab in Men with Metastatic Castration-resistant Prostate Carcinoma(mCRPC). American Society for Clinical Oncology, 2016.
18. Uemura MI, Haymaker C, James M, Cornfeld M, Chunduru S, Agrawal S, Hwu WJ, Davies M, Glitza IC, Patel SP, Amaria R, Yee C, Tawbi HA, Woodman SE, Hwu P, Sharma P, Allison J, Hailemichael Y, Bernatchez C, Diab A. A phase 1/2, open-label, single-institution study of intratumoral IMO-2125 in combination with systemic ipilimumab in patients with metastatic melanoma. American Society for Clinical Oncology, 2016.
19. Janjigian Y, Bendell J, Calvo E, Kim JW, Ascierto P, Sharma P, Ott PA, Bono P, Jaeger D, Evans J, Braud F, Chau I, Tschaika M, Harbison C, Lin CS, Le DT. CheckMate-032: phase 1/2, open-label study of safety and activity of nivolumab (nivo) alone or with ipilimumab (ipi) in advanced and metastatic (A/M) gastric cancer (GC). American Society for Clinical Oncology, 2016.
20. Motzer RJ, Sharma P, Escudier B, McDermott D, Geroge S, Srinivas S, Tykodi SS, Sosman JA, Plimack ER, Nathan P, Grunwald V, Tomita Y, Zhao H, Waxman IM, Hammers HJ. Correlation of response with overall survival (OS) for nivolumab vs everolimus in advanced renal cell carcinoma (aRCC): Results from the phase III CheckMate 025 study. American Society for Clinical Oncology, 2016.
21. Sharma P, Bono P, Kim J, Spiliopoulou, Calvo E, Pillai R, Ott P, DeBraud F, Morse M, Le D, Jaeger D, Chan E, Harbison C, Lin CS, Tschaika M, Azrilevich A, Rosenberg J. Efficacy and safety of nivolumab monotherapy in metastatic urothelial cancer (mUC): Results from the phase I/II CheckMate 032 study. American Society for Clinical Oncology, 2016.
22. Goswami S, Zhao H, Zhang X, Sharma P. Epigenetic changes in T cells in response to immune checkpoint blockade. American Society for Clinical Oncology, 2016.
23. Reilley M, Blando J, Katkhuda R, Menter D, Sharma P, Allion J, Kopetz S, Maru D, Overman M. Immunologic profiling of consensus molecular subtype (CMS) stratified colorectal cancer (CRC) primary and liver metastatectomy specimens: Implications for immune targeting of proficient mismatch repair CRC. American Society for Clinical Oncology, 2016.
24. Fuji T, Colen R, Bilen AM, Hess K, Hajjar J, Suarez-Almazor ME, Hong DS, Janku F, Subbiah V, Kato S, Karp DD, Piha-Paul SA, Tsimberidou AM, Fu S, Sharma P, Meric-Bernstam F, Naing A. Incidence of Immune-related adverse events in patients who received immunotherapy and radiographic analysis to predict pneumonitis. American Society for Clinical Oncology, 2016.
25. Bajorin DF, |Sharma P, Quinn DI, Plimack ER, Hoffman-Censits JH, O'Donnell PH, Siefker-Radtke AO, Sheikh NA, LlllJS, Trager JB, Gomella LG. Phase 2 trial results of DN24-02, a HER2-targeted autologous cellular immunotherapy in HER2+ urothelial cancer patietnts (pts). American Society for Clinical Oncology, 2016.
26. Reilley M, Bailey A, Subbiah V, Janku F, Naing A, Falchook G, Karp D, Piha-Paul S, Tsimberidou A, Fu S, Zinner R, Lim J, Bean S, Bass A, Montez S, Vence L, Sharma P, Allison J, Meric-Bernstam F, Hong D. Phase I clinical trial of combination Imatinib and Ipilimumab in patients with advanced malignancies. American Society for Clinical Oncology, 2016.
27. Escudier B, Motzer RJ, Sharma P, Wagstaff J, Plimack ER, Hammers HJ, Donskov F, Gurney H, Sosman JA, Zalewski PG, Harmenberg U, mCDermott DF, Choueiri TK, Richardet M, Tomita Y, Ravaud A, Doan J, Zhao H, Hardy H, Geroge S. Treatment beyond progression with nivolumab (nivo) in patients (pts) with advanced renal cell carcinoma (aRCC) in the phase III CheckMate 025 study. American Society for Clinical Oncology, 2016.
28. Tang C, Welsh J, Groot P, Massarelli E, Chang J, Hess K, Curran M, Cabanillas M, Subbiah V, Fu S, Tsimberidou A, Karp DD, Gomez DR, Komaki R,Sharma P, Naing A, Hong DS. Phase I trial combining ipilimumab + high dose stereotactic radiation: results and serum immune correlates. American Society for Clinical Oncology, 2016.
29. Morris Van, Ciombor KK, Salem M, Nimeiri HS, Iqbal S, Singh PP, Polite B, Deming S, Chan E, Wade III JL, Bekaii-Saab T, Uronis H, Pasia M, Bland G, Wolff R, Ohinata A, Ohaji C, Rogers J,Sharma P, Eng C. A Multi-Institutional ETCTN Phase 2 Study of Nivolumab in Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal (SCCA). American Society for Clinical Oncology, 2016.
30. Daver N, Basu S, Guillermo GM, Cortes J, Ravando F, Komblau S, Konopleva M, Andreeff M, Borthakur G, Jain N, Wierda W, Ruvolo P, Matthews J, Flores W, Yang H, Verstovsek S, Bueso-Ramos C, Somani N, Blando J, Allison J, Kantarjan H, Sharma P. Defining the immune checkpoint landscape of acute myeloid leukemia (AML). American Association for Cancer Research, 2016.
31. Massarelli E, Parra E, Diao L, Wang J, Jaime RC, Behrens C, Blando J, Byers L, Wistuba I, Sharma P, Allison J, Heymach J. High OX-40 expression on the tumor immune infiltrate is a prognostic factor of better overall survival in non-small cell lung cancer. American Association for Cancer Research - CRI-CIMT-EATI International Cancer Immunotherapy Conference, 2016.
32. Daver N, Cortes J, Ravandi F, Basu S, Garcia-Manero G, Jabbour E, Hendrickson S, Pierce S, Ning J, Konopleva M, Andreeff M, Borthakur G, Pemmaraju N, Bueso-Ramos C, Blando J, Allison J, Kantarjian H, Sharma P. Nivolumab in Combination with Azacytidine in Patients with Relapsed Acute Myeloid Leukemia. ASH 2016 Annual Meeting, 2016.
33. Daver N, Basu S, Cortes J, Ravandi F, Garcia-Manero G, Jabbour E, Hendrickson S, Pierce S, Ning J, Konopleva M, Andreeff M, Borthakur G, Pemmaraju N, Bueso-Ramos C, Blando J, allison J, Kantarjian H, Sharma P. Lirilumab in Combination with Azacytidine in Patients with Relapsed Acute Myeloid Leukemia. ASH 2016 Annual Meeting, 2016.
34. Sharma P. From the clinic to the lab: Investigating immune responses to immune checkpoint therapies. 22nd Annual International Cancer Immunotherapy Symposium, 2014.
35. Sharma P. Investigating the role of the ICOS/ICOSL pathway in mediating anti-tumor responses in the setting of CTLA-4 blockade. Penn State College of Medicine, Penn State Hershey Cancer Institute, 2012.
36. Sharma P. Novel Approaches to Assessing T-Cell Function and Reactivity. American Society for Clinical Oncology 2012 Markers in Cancer, 2012.
37. Gao JJ, Sun J, Ward J, Rao P, Troncoso P, Araujo J, Ng Tang D, Chen H, Thall P, Wen S, Sharma P. Combination therapy with anti-CTLA-4 plus leuprolide acetate in the pre-surgical setting of patients with regional, high-risk prostate cancer. American Association for Cancer Research, 2012.
38. Gao JJ, Chen H, Ng Tang D, Sharma P. Investigating genes and pathways that play a role in immune responses mediated by anti-CTLA-4 therapy. American Society of Clinical Oncology, 2012.
39. Aparicio A, Sun JJ, Ng Tang D, Arap W, Araujo J, Corn P, Tannir N, Wang X, Sharma P. A Phase II Study of Ipilimumab Plus Androgen Deprivation Therapy in Castration-sensitive Prostate Carcinoma. American Association for Clinical Research, 2012.
40. Bajorin DF, Sharma P, Sims RB, Sandler A, Lerner SP. Design of a Phase 2 randomized, open-label trial of DN24-02, an autologous cellular immunotherapy targeting HER2/neu, in patients with surgically resected urothelial cancer at high risk of recurrence. American Society of Clinical Oncology, 2012.
41. Sharma P. Anti-CTLA-4 therapy requires the ICOS/ICOSL pathway to mediate optimal anti-tumor responses. Center for Immune Modulatory Therapies for Autoimmunity and Cancer, Karolinska Institutet, Ljusterö, Sweden, 2011.
42. Sharma P. CTLA-4 and ICOS as cancer immunotherapy targets. American Association for Cancer Research, 2011.
43. Sharma P. Implicating the ICOS/ICOSL Pathway as a Target for Cancer Immunotherapy. Clinical Immunology Society, 2011.
44. Sharma P. Investigating the ICOS/ICOSL pathway as a target to improve anti-tumor responses mediated by CTLA-4 blockade. Translational Research Seminar, Mt. Sinai School of Medicine, 2011.
45. Sharma P. Immune monitoring of CTLA-4 blockade on a pre-surgical clinical trial: Implicating the ICOS/ICOSL pathway in anti-tumor immune responses. Hematology and Medical Oncology Grand Rounds, Memorial Sloan-Kettering Cancer Center, 2011.
46. Sharma P. Immunologic Consequences of Renal Ablation and Rationale for Combination Renal Ablation/Immunomodulation Strategies. MD Anderson Cancer Center Kidney Multidisciplinary Research Program, 2011.
47. Sharma P. Novel agents and targets in immunotherapy. First Annual Kidney Cancer Collaborative Symposium, MD Anderson Cancer Center Kidney Multidisciplinary Research Program, 2011.
48. Sharma P. Management of Metastatic Clear Cell RCC (1) Immunotherapeutic Approaches, Old and New. MD Anderson Cancer Center Department of Genitourinary Medical Oncology Courses on Renal Cell Carcinoma, 2011.
49. Sharma P. Immunology: From Bench to Bedside and Back. Translational Science: From Bench to Bedside and Back, MD Anderson Cancer Center Department of Investigational Cancer Therapeutics, 2011.
50. Sharma P. Assessment of biologic impact of immunotherapeutic agents. American Association for Cancer Research, 2010.
51. Sharma P. Defining the Role of Inducible Co-stimulator (ICOS)-Expressing T Cells Against Melanoma. Melanoma Research Association, 2010.
52. Sharma P. Immune monitoring of CTLA-4 blockade on a pre-surgical clinical trial: Implicating the ICOS/ICOSL pathway in anti-tumor immune responses. American Association for Cancer Research - Tumor Immunology, 2010.
53. Sharma P. Pre-operative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial. Canadian Society of Immunology, 2010.
54. Sharma P. Pre-surgical Clinical Trials in Cancer Patients to Identify Biomarkers of Immunotherapy. Clinical Immunology Society, 2010.
55. Sharma P. Prostate Cancer Immunotherapy: Immune Responses Mediated by CTLA-4 Blockade. Free University Amsterdam Prostate Cancer Symposium, 2010.
56. Sharma P. Role of ICOS-expressing T Cells in Anti-tumor Responses Mediated by CTLA-4 Blockade. Basic Science Distinguished Lecturer Program, Washington University School of Medicine, 2010.
57. Sharma P. Pre-operative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial. Department of Immunology Seminar, Ontario Cancer Institute, Princess Margaret Hospital, 2010.
58. Sharma P. Monitoring Immune and Clinical Responses to Anti-CTLA-4 Therapy. University of Connecticut Center for Immunotherapy of Cancer and Infectious Diseases, Health Center Seminar Series, 2010.
59. Sharma P. Immune responses mediated by CTLA-4 blockade. ABCAM Immune Tolerance in Cancer and Autoimmune Disease Conference, 2009.
60. Sharma P. Immunologic Impact of Anti-CTLA-4 Therapy. American Society of Clinical Oncology Annual Meeting, 2009.
61. Sharma P. Immune Responses Mediated by CTLA-4 Blockade. Melanoma Research Alliance Annual Meeting, 2009.
62. Sharma P. Systemic Chemotherapy for Urothelial Carcinoma. MD Anderson Cancer Center 9th Annual Oncology Update: Advances and Controversies, 2009.
63. Sharma P. Immunologic Impact of Anti CTLA-4 Therapy. American Association for Cancer Research Annual Meeting, 2009.
64. Sharma P. Immunize Responses Mediated by CTLA-4 Blockade. Keystone Symposia: Mobilizing Cellular Immunity for Cancer Therapy, 2009.
65. Sharma P. Is there Still a Role for Immunotherapy in the Treatment of Metastatic Renal Cell Carcinoma. MD Anderson Cancer Center - Urology Oncology Conference, 2009.
66. Sharma P. Assessment of Biologic Impact of Immunotherapeutic Agents. American Association for Cancer Research Molecular Biology Clinical Oncology Workshop, 2009.
67. Sharma P, Kamat A, Ng Tang D, Chen H, Fu T, Sun J, Troncoso P, Yuan J, Wolchok J, Queada S, Logothetis C, Allison J. Assessing immunologic impact of anti-CTLA-4 therapy on a presurgical clinical trial. Proc Amer Assoc Can Res:Abstr 5665, 2009.
68. Sharma P. Functional and Phenotypic Impact of Anti-CTLA-4 Antibody in the Pre-surgical Setting. American Association for Cancer Research Annual Meeting, 2008.
69. Sharma P. Immunologic Impact of Anti-CTLA-4 Therapy. Cancer Research Institute Annual Meeting, 2008.
70. Sharma P. Immunotherapy for Renal Cell Carcinoma. MD Anderson Cancer Center, 2008.
71. Sharma P. Immune Responses Mediated by CTLA-4 Blockade. American Association for Cancer Research Annual Meeting, Plenary Session, 2008.
72. Sharma P. Immunology Impact of Anti-CTLA-4 Antibody in a Neoadjuvant Setting. Cancer Research Institute Annual Meeting, 2007.
73. Sharma P. Immunotherapy for Prostate Cancer. Prostate Cancer Foundation Annual Meeting, 2007.
74. Sharma P. Monitoring Immune Response in Patients Treated with Immunotherapy, Physician-Scientist/Clinician Investigator Update. MD Anderson Cancer Center Pioneers Group, 2007.
75. Sharma P. Studying Immune Responses to the NY-ESO-1 Antigen in Transitional Cell Carcinoma Patients. MD Anderson Cancer Center Genitourinary Medical Oncology Bladder SPORE, 2007.
76. Sharma P. CD8+ Tumor-Infiltrating Lymphocytes as a Statistically Significant Marker of Disease Recurrence and Survival in Transitional Cell Carcinoma Patients. American Society of Clinical Oncology Annual Meeting, 2006.
77. Sharma P. Regulatory T-cells Are Increased in the Tumor Microenvironment of Prostate Cancer Patients. Cancer Research Institute Annual Meeting, 2006.
78. Sharma P. Immunological Studies in Prostate Cancer. MD Anderson Cancer Center - Center for Cancer Immunology, 2006.
79. Sharma P. Protein and DNA-based Vaccines With NY-ESO-1 Antigen in Cancer Patients. International Society for Biological Therapy of Cancer Annual Meeting, 2005.
80. Sharma P. Combinatorial Targeting of the NY-ESO-1 Cancer Testis Antigen. Cancer Research Institute Annual Meeting, 2005.
81. Sharma P. Protein and DNA-based Vaccines with the NY-ESO-1 Antigen in Cancer Patients. National Cancer Institute Center of Excellence in Immunology, 2005.

Book Chapters

1. Campbell MT, Sharma A, Goswami S, Sharma P. Tumor Immunotherapy. In: Clinical Immunology: Principles and Practice, 5th Edition, 2016.
2. Callahan MK, Wolchok JD, Allison JP, Sharma P. Immune Co-signaling to Treat Cancer. In: Cancer Immunotherapy: Paradigms, Practice and Promise. 211-280. Springer: New York, 211-280, 2013.
3. Lizée G, Overwijk WW, Radvanyi L, Gao J, Sharma P, Hwu P. Harnessing the power of the immune system to target cancer. In: Annu Rev Med. 71-90, 71-90, 2013.
4. Peggs KS, Quezada SA, Sharma P, Allison JP. Chapter 13: Cancer Immunotherapy. In: Cancer Medicine 9th Edition, 2010.